LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA , June 10, 2024 /PRNewswire/ -- Flamingo Therapeutics ('Flamingo') today announced a poster presentation on FLM-7523 (also referred to as FTX-001) at the Annual Congress of the European Association for Cancer Research (EACR) 2024 Congress, being held in Rotterdam, Netherlands from June 10-13, 2024..

比利时鲁汶、法国斯特拉斯堡和费城，2024年6月10日/PRNewswire/--火烈鸟治疗公司（“火烈鸟”）今天宣布，在2024年6月10日至13日于荷兰鹿特丹举行的欧洲癌症研究协会（EACR）2024年会年会上，FLM-7523（也称为FTX-001）上发布了海报。。

Flamingo will present preclinical results highlighting the candidate selection and characterization of FLM-7523, a novel oligonucleotide targeting MALAT1 for the treatment of cancer. Flamingo has advanced FLM-7523 through Phase 1 enabling preclinical activities and is planning for a First-in-Human trial in solid tumors..

Flamingo将展示临床前结果，重点介绍FLM-7523的候选选择和表征，FLM-7523是一种靶向MALAT1的新型寡核苷酸，用于治疗癌症。Flamingo已将FLM-7523推进到第一阶段，实现了临床前活动，并计划在实体瘤中进行首次人体试验。。

EACR poster details are as follows:

EACR海报详情如下：

Abstract#: EACR2024-0240

摘要#：EACR2024-0240

Title: 'Preclinical development of FTX-001: First-in-class inhibitor of the long non-coding RNA MALAT1'

标题：“FTX-001的临床前开发：长非编码RNA MALAT1的一流抑制剂”

Session Title: Posters: Experimental/Molecular Therapeutics, Pharmacogenomics

课程名称：海报：实验/分子疗法，药物基因组学

Session Date and Time: June 11, 2024, from 11:00 to 20:15

会议日期和时间：2024年6月11日11:00至20:15

Presenting Author: Dr. Marie-Aline Neveu

演示作者：Marie Aline Neveu博士

Abstracts related to the EACR meeting will be published online in a supplement to the FEBS journal, Molecular Oncology, the Congress App and the Congress Website. For more information, please visit the EACR 2024 website.

与EACR会议相关的摘要将在线发布在FEBS期刊，分子肿瘤学，大会应用程序和大会网站的补充中。有关更多信息，请访问EACR 2024网站。

About Flamingo Therapeutics

关于Flamingo Therapeutics

Flamingo is pioneering RNA-targeted therapies for oncology with a clinical-stage pipeline targeting undruggable transcription factors and long non-coding RNAs. Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Abrdn (formerly funds managed by Tekla Capital Management LLC), Andera Partners, Bpifrance Large Venture, Bpifrance through its FABS and Fonds Biothérapies Innovantes et Maladies Rares funds, Eurazeo - Kurma Partners, Perceptive Advisors, PMV, Pontifax, Sphera, and VIB..

Flamingo是针对肿瘤的RNA靶向疗法的先驱，其临床阶段管道靶向不可药用的转录因子和长的非编码RNA。Flamingo与Ionis Pharmaceuticals建立了联盟，并得到了知名生物技术投资者的支持，包括Abrdn（以前由Tekla Capital Management LLC管理的基金）、Andera Partners、Bpifrance Large Venture、Bpifrance及其FABS和Fonds Biothérapies Innovantes et Maladies Rares funds、Eurazeo-Kurma Partners、Perceptive Advisors、PMV、Pontifax、Sphera和VIB。。

Flamingo has initiated a Phase II trial 'PEMDA-HN' evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck squamous cell carcinoma (HNSCC). A Phase I investigator-initiated trial study has also been initiated evaluating danvatirsen as a monotherapy and in combination with venetoclax in AML/MDS patients..

Flamingo启动了一项II期试验“PEMDA-HN”，评估STAT3靶向药物danvatirsen与pembrolizumab联合用于头颈部鳞状细胞癌（HNSCC）患者。一项由研究者发起的I期试验研究也已开始评估danvatirsen作为单一疗法，并与venetoclax联合用于AML/MDS患者。。

For more information on Flamingo, please visit:

有关火烈鸟的更多信息，请访问：

https://flamingotx.com

https://flamingotx.com

PEMDA-HN (head and neck cancer) on clinicaltrials.gov:

clinicaltrials.gov上的PEMDA-HN（头颈癌）：

https://clinicaltrials.gov/study/NCT05814666

https://clinicaltrials.gov/study/NCT05814666

Danvatirsen monotherapy followed by combination with venetoclax in relapsed/ refractory AML and MDS on clincaltrials.gov:

Danvatirsen单药治疗，然后在clincaltrials.gov上联合venetoclax治疗复发/难治性AML和MDS：

https://classic.clinicaltrials.gov/ct2/show/NCT05986240

https://classic.clinicaltrials.gov/ct2/show/NCT05986240

Please engage with us on LinkedIn:

请在LinkedIn上与我们联系：

https://www.linkedin.com/company/flamingo-therapeutics.

https://www.linkedin.com/company/flamingo-therapeutics.

Flamingo Media and Investor Contact:

Flamingo Media和投资者联系人：

Amy Conrad

艾米·康拉德

Juniper Point

Juniper点

(858) 366-3243

(858) 366-3243

amy@juniper-point.com

amy@juniper-point.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/flamingo-therapeutics-announces-poster-presentation-at-eacr-2024-congress-on-flm-7523-ftx-001-a-first-in-class-inhibitor-of-the-long-non-coding-rna-malat1-302167874.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/flamingo-therapeutics-announces-poster-presentation-at-eacr-2024-congress-on-flm-7523-ftx-001-a-first-in-class-inhibitor-of-the-long-non-coding-rna-malat1-302167874.html

SOURCE Flamingo Therapeutics

来源火烈鸟治疗